US-based bioelectronic medicine company Cala Health has rolled out its next-generation Cala kIQ System to help manage action hand tremors in people with essential tremor and Parkinson’s disease (PD).

The system is indicated for temporary relief of postural and kinetic hand tremor symptoms in the treated hand following stimulation in adults with Parkinson’s disease.

It provides an on-demand, at-home therapy to help patients and physicians easily use and manage action hand tremors.

The system delivers transcutaneous afferent patterned stimulation (TAPS) therapy, which is validated by large clinical studies and real-world evidence.

Cala kIQ is the first and only FDA-approved wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and PD, said the company.

Cala CEO Renee Ryan said: “At Cala, we’ve always been committed to expanding patient access and accelerating innovation in TAPS therapy for indications beyond essential tremor.

“By expanding into Parkinson’s disease, we are now able to bring this powerful treatment to additional patients who suffer from action hand tremors.”

Action hand tremors occur when the patient undergoes intentional movement or posture, and its treatment options include medications, and surgery in severe cases.

Leveraging TAPS therapy, Cala kIQ System provides a non-invasive, and non-pharmacologic solution with minimal side effects.

It measures each patient’s unique tremor physiology and customises a stimulation pattern for tremor relief, delivered through a wrist-worn wearable.

The easy-to-use system allows patients to view their therapy session results over time and can share them with their providers to adjust treatment plans.

Cala Health said that the Cala kIQ System is covered by the Veterans Affairs (VA) Health System at no cost to VA beneficiaries.

The company is working to secure additional coverage and reimbursement for the new PD indication for the Cala kIQ System.